Cannabis is the most frequently used illicit psychoactive substance worldwide; around one in ten users become dependent. The risk for cannabis use disorder (CUD) has a strong genetic component, with twin heritability estimates ranging from 51 to 70%. Here we performed a genome-wide association study of CUD in 2,387 cases and 48,985 controls, followed by replication in 5,501 cases and 301,041 controls. We report a genome-wide significant risk locus for CUD (P = 9.31 × 10 −12
Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. *e-mail: ditte@biomed.au.dk; anders@biomed.au.dk C annabis use is increasing in the population 1 and around 9% of users become dependent 2 . Genetic factors explain a large proportion of the risk for cannabis use disorder (CUD) with twin heritability estimates in the range of 51-70% 3, 4 . The prevalence of diagnosed CUD in the population has been estimated to 1-1.5% in Europeans 5 and Americans
1
. CUD is associated with a range of health problems 6 including risk of psychosis 7 , bipolar disorder 8 , anxiety disorder 9 and cognitive impairment, with more persistent use associated with greater decline 10 . Estimates of the heritability for cannabis use initiation and lifetime cannabis use, regarding the amount of variance explained by common variants (that is, single nucleotide polymorphism (SNP) heritability), has been estimated to 0.06-0.2 (refs. 11, 12 ). Four genome-wide association studies (GWASs) related to cannabis use initiation or lifetime use have been conducted; three without genome-wide significant findings [11] [12] [13] and a large GWAS meta-analysis of lifetime cannabis use including 184,765 individuals, which identified eight genome-wide significant independent risk loci 14 . Four GWASs of problematic use or diagnosed CUD have been conducted; two without genomewide significant findings 15, 16 and two recently reporting genomewide significant associations, albeit with negative or ambiguous replication results: a study of Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV) cannabis dependence criterion counts in a combined sample of 14,754 European Americans and African Americans 17 , which reported three genome-wide significant loci associated with cannabis use severity, and a GWAS of cannabis dependence of 2,080 European cases and 6,435 controls, which identified one genome-wide significant locus 18 .
Here, we present results from a GWAS and subsequent replication based on analyses of the largest cohorts of diagnosed CUD reported so far. Individuals included in the discovery GWAS come from the Danish nationwide population-based cohort collected by the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH). The iPSYCH cohort was established to study six Articles Nature NeuroscieNce major psychiatric disorders (schizophrenia, bipolar disorder, major depressive disorder (MDD), attention-deficit hyperactivity disorder (ADHD), anorexia nervosa and autism spectrum disorder (ASD)) and consists of 79,492 genotyped individuals. The present GWAS included 2,387 individuals with a diagnosis of CUD. In this study, CUD was defined by individuals having an International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) diagnosis reflecting a problematic and persistent use of cannabis (ICD-10 F12.1-12.9; see Supplementary Tables 1-3 for information on the number of cases in each diagnostic subcategory and the distribution over the diagnostic subcategories in relation to comorbid psychiatric disorders) and 48,985 individuals not diagnosed with CUD, all from the iPSYCH cohort. We identify a genome-wide significant risk locus on chromosome 8, which replicates in an independent cohort from deCODE genetics. The index variant is a strong expression quantitative trait locus for cholinergic receptor nicotinic α2 subunit (CHRNA2), which encodes the neuronal acetylcholine receptor (nAChR) α2 subunit. In analyses of the genetically regulated gene expression, we find reduced expression of CHRNA2 in brain tissue in individuals with CUD. At the polygenic level, we show that increased load of the variants associated with decreased cognitive performance, risk of schizophrenia and ADHD are associated with increased CUD risk.
Results

GWAS of CUD and replication in an independent cohort from
Iceland. Data analysis was conducted using the Ricopili pipeline 19 , including stringent quality control of genotyped variants and individuals (Methods). Information about non-genotyped markers was obtained by imputation using phase 3 of the 1000 Genomes Project as the reference panel. The GWAS was performed using imputed marker dosages and an additive logistic regression model with the following covariates: relevant principal components to correct for confounders such as population stratification; presence of the major psychiatric disorders studied in iPSYCH; and genotyping wave. Only markers with an imputation INFO score > 0.7, minor allele frequency (MAF) > 0.01 and biallelic variants were retained; in total, 8,971,679 genetic variants were included. We identified 26 genome-wide significant variants (P < 5 × 10 ) with regard to the minor allele A (Table 1; Figs. 1 and 2). We found no signs of contributions from confounding factors, such as population stratification and cryptic relatedness, to the inflation in the distribution of the test statistics (λ = 1.033; see Fig. 1b , quantilequantile plot) using linkage disequilibrium score regression, since the intercept was practically 1 (intercept = 0.996; s.e.m. = 0.0079; see Methods). There was no evidence of association of previously identified genome-wide significant cannabis use risk variants with CUD in our analyses 17, 18 (Supplementary Table 5 ). This might be due to different phenotype definitions among studies since Sherva et al. 17 analyzed the association with cannabis use criterion counts and Agrawal et al. 18 used cannabis-exposed (but not dependent) individuals as controls in their study. Additionally, the composition of the cohorts analyzed is also different since the previous GWASs were based on cohorts established to study substance use disorders while the iPSYCH cohort was established to study major mental disorders.
The genome-wide significant locus on chromosome 8 was replicated in an independent Icelandic sample consisting of 5,501 cases with CUD and 301,041 population controls (the deCODE cohort). The cases were diagnosed with CUD while undergoing inpatient treatment at the SAA National Center of Addiction Medicine, Vogur Hospital in Iceland (www.saa.is). SAA treats around 80% of individuals with substance abuse in Iceland; this makes the deCODE CUD cohort nearly population-wide 20 . We tested nine variants located in the risk locus in the Icelandic sample; the index variant and eight correlated variants (0.2 < r 2 < 0.7) with P < 1 × 10 −6 (four genomewide significant). All variants demonstrated consistent direction of association. The most strongly associated variant (rs56372821) in the discovery GWAS showed a P value of 3.27 × 10 −3 in the deCODE cohort, however, with a slightly smaller effect size (Table 1 ). In the meta-analysis, rs56372821 showed a slightly stronger association with CUD (P = 9.09 × 10 −12
), and an additional two variants became genome-wide significant (Table 1) .
We performed polygenic risk score (PRS) analysis to evaluate the consistency between the deCODE and iPSYCH CUD phenotypes. When using the iPSYCH cohort as the discovery GWAS, we observed a significant association of CUD PRS in the deCODE cohort with CUD (P = 2.17 × 10 −9
; P threshold < 0.01 in the discovery GWAS) but not with schizophrenia or bipolar disorder (Supplementary Table 4 ), suggesting that the associations in the iPSYCH cohort are primarily driven by CUD and not the comorbid psychiatric disorders.
To assess the proportion of phenotypic variance in the iPSYCH data explained by common variants, we applied linkage disequilibrium score regression and the genome-based restricted maximum likelihood method implemented in genome-wide complex trait analysis (GCTA), assuming a population prevalence of 1% for CUD (see Methods). Estimates of liability-scale SNP heritability were h 2 SNP = 0.09 (s.e.m. = 0.03) and h 2 SNP = 0.042 (s.e.m. = 0.014; P = 0.0012) using linkage disequilibrium score regression and GCTA, respectively. This result suggests a smaller contribution from common variants than was previously found for cannabis use 12 . The estimate will probably increase with larger sample sizes because of a decrease in the size of the error terms of the SNP effect estimates 21 .
Role of the CUD risk locus in other psychiatric disorders. In the GWAS, we corrected for diagnoses of the major psychiatric disorders studied in the iPSYCH cohort (see Supplementary Table 1 for the distribution of psychiatric disorders in the CUD cases and controls). In addition, we evaluated the impact on the OR for the index variant using leave-one-phenotype-out analyses, excluding psychiatric phenotypes one at a time in the association analysis (see Methods). The OR remained stable ( Table 2 ), suggesting that the association was independent of a diagnosis of the psychiatric disorders being evaluated.
The risk locus on chromosome 8 is also genome-wide significantly associated with schizophrenia 19 . In our leave-one-phenotype-out analysis, the locus remained significant genome-wide when individuals with schizophrenia were removed, excluding any potential confounding from schizophrenia (Table 2 ). Additionally, we tested the possibility of the locus being broadly associated with psychiatric disorders by performing a cross-disorder GWAS that included 35,006 individuals with at least one of the five major psychiatric disorders and 16,366 controls. In this analysis, the index variant (rs56372821) showed a P value of 0.058 (OR = 0.966). When the GWAS was rerun while excluding all individuals with CUD, the analysis revealed a cross-disorder P = 0.33 and OR = 0.982 for rs56372821 (32,716 cases and 16,269 controls). The close-to-nominally significant signal observed in the cross-disorder GWAS, which included all cases, disappeared when excluding individuals with a CUD diagnosis. This reinforces the notion that the association signal in the CUD GWAS is caused by CUD and not by a general association with psychiatric disorders.
The signal observed for the index variant in the GWAS metaanalysis of schizophrenia 19 (rs73229090) is consistent with the direction of the association observed in our analysis. Since individuals with schizophrenia often use cannabis (around 13-16% 22 ), it could be speculated that the significant signal observed in schizophrenia is driven by a subgroup of schizophrenia cases also having CUD. This hypothesis is supported by the analysis of the association of ). The index variant is highlighted as a green diamond; the SNPs in high linkage disequilibrium with the index SNP are marked in green. b, Quantile-quantile plot of the expected and observed P values from the GWAS of CUD (2,387 individuals with CUD and 48,985 controls). The blue line indicates the distribution under the null hypothesis; the shaded area indicates the 95% confidence interval. Articles Nature NeuroscieNce rs56372821 with schizophrenia in the iPSYCH sample. We found a nominally significant association of the variant with schizophrenia when including individuals with comorbid CUD (2,281 schizophrenia cases and 23,134 controls; OR = 0.9; P = 0.036), whereas after exclusion of individuals with CUD (556 cases and 101 controls) the association signal disappeared (1,727 cases, 23,033 controls; OR = 0.97, P = 0.63). To further evaluate the impact of CUD comorbidity on the OR of rs56372821 in schizophrenia, a null distribution for the OR was generated by performing 10,000 permutations, randomly removing 556 and 101 individuals among the cases and controls, respectively ( Supplementary Fig. 1 ). The observed OR for rs56372821, when individuals with comorbid CUD were excluded, was 0.97; it differed significantly from the random removal of the same number of cases and controls (two-sided P = 0.0027, onesided P = 0.0015). Thus, the permutation test supports the hypothesis that the subgroup diagnosed with CUD among schizophrenia cases drives the nominal association observed for rs56372821 in the iPSYCH schizophrenia sample. Transcriptome-wide association study implicates CHRNA2 in CUD. Among the brain tissues analyzed in the Genotype-Tissue Expression (GTEx) project (https://gtexportal.org/home/), the index variant rs56372821 was found to be a strong expression quantitative trait locus for CHRNA2 in the cerebellum (P in GTEx = 2.1 × 10 −7 ), with the risk allele (rs56372821-G) being associated with decreased expression of the gene (Supplementary Fig. 2 ). CHRNA2 is expressed in the brain and encodes the nAChR α2 subunit, which is incorporated in heteropentameric neuronal nAChRs mainly with the β2 or β4 subunits 23 . Candidate gene studies of common variants have linked this gene to, for example, substance abuse 24 and nicotine dependence 25 ; however, no genome-wide significant findings have connected CHRNA2 to any substance abuse or psychiatric disorder besides a functional link between schizophrenia risk variants and CHRNA2 expression identified by Won et al. 26 .
To further evaluate the potential regulatory impact of the identified locus on chromosome 8, as well as genome-wide gene expression differences between cases and controls, we imputed the genetically regulated gene expression in 11 brain tissues using PrediXcan v.6 (see Methods). The SNP weights used were derived from models trained on reference transcriptome datasets including ten brain tissues from the GTEx and transcriptome data from dorsolateral prefrontal cortex generated by the CommonMind Consortium. We tested for association of expression of 2,460-10,930 protein-coding genes with CUD, depending on the tissue (Supplementary Table 6 ), using logistic regression corrected by the same covariates as in the GWAS. One gene, CHRNA2, was significantly differently expressed between cases and controls (P = 2.713 × 10 −6 ; β = −0.21; s.e.m. = 0.045) in the cerebellum. The expression model for CHRNA2 in the cerebellum was based on 47 SNPs including 4 genome-wide significant SNPs-rs59724122, rs73229093, rs7838316 and rs11783093 (Fig. 3) . CHRNA2 expression was predicted with a valid model in two other brain tissues, showing nominally significant underexpression in cases compared to controls (dorsolateral prefrontal cortex, P = 5.19 × 10 ; cerebellar hemisphere P = 5.30 × 10
−3
). That the risk locus for CUD can be linked to CHRNA2 expression is also supported by Won et al. 26 who Table 1 in the controls, the OR for the effect of A1 and P values (two-sided P values from the logistic regression of the iPSYCH and deCODE cohorts and from the inverse variance-weighted fixed effects meta-analysis) are shown. Bolding of P values indicates genome-wide significance.
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Nature NeuroscieNce generated high-resolution three-dimensional maps of chromatin contacts (using the Hi-C sequencing approach) to capture functional relationships between regulatory and transcribed elements during human corticogenesis. They applied their map to a set of credible SNPs from the large Psychiatric Genomics Consortium schizophrenia GWAS 19 and found physical interaction of the genome-wide significant risk locus on chromosome 8 with the regulatory region of CHRNA2.
Examination of smoking behavior as a confounder. CHRNA2 is related to other nicotine receptor genes that have been identified as risk loci for nicotine dependence and smoking behavior 27 . Therefore, it is relevant to question if our finding is confounded by smoking. In the iPSYCH cohort, there is no available information about smoking behavior. As much as 70-90% of cannabis users are reported to also smoke cigarettes 28 , which impose the risk of confounding. However, smoking is also highly comorbid with psychiatric disorders 29 , which is prevalent in the control group (66,79% were diagnosed with at least one of the major psychiatric disorders studied in iPSYCH; Supplementary Table 1 ). Since we expect smoking to be prevalent both among cases and controls, it is unlikely that smoking alone would generate the high effect size we observe for the risk locus on chromosome 8. However, in the recent GWAS meta-analysis of smoking 30 , which included more than 1.2 million people, the CUD risk locus is significantly associated with smoking genome-wide, with the CUD risk allele increasing the risk for smoking initiation, younger age at smoking initiation and continuation of smoking; however, it is associated with a decreasing number of cigarettes per day (Supplementary Table 7 ). The strongest association is observed for smoking initiation with an effect size OR = 0.954 (rs11783093), which is significantly lower than the effect size observed for CUD in the iPSYCH cohort (OR = 0.73 (rs56372821); P = 7.96 × 10 −09
; Z = 5.767) and smaller than in the deCODE cohort (OR = 0.88; P = 0.061; Z = 1.87). This suggests that the locus has a pleiotropic effect on the risk of both smoking and CUD in the general population, with the greatest impact on CUD risk. To rule out that smoking behavior is not the main factor driving the association signal on chromosome 8 in the present study, we performed several additional analyses.
First, the results from the CUD GWAS were adjusted by conditioning on the effects of a set of independent, associated variants with smoking initiation 30 using mtCOJO (see Methods). The results, which are robust to confounding by shared genetic and environmental factors with smoking, suggests that the association with CUD is not strongly confounded by smoking (OR corrected = 0.759; P = 4.44 × 10 −9
, Supplementary Table 8) . Furthermore, we evaluated by elementary simulation analysis how likely it would be to observe an OR of 0.728 if the signal was primarily driven by tobacco smoking, by assuming a true OR of smoking of 0.954 (ref. 30 ). We assigned plausible values for the prevalence of tobacco smoking among minor and major allele carriers of rs5637282, as well as CUD among tobacco users and non-users, and empirically approximated the probability of observing an OR of 0.728. The largest P value encountered was 8.69 × 10 −3 (2 12 scenarios were tested), supporting that it is very unlikely that the OR we observed for CUD could be caused by tobacco smoking alone (see Methods and Supplementary Table 9) .
Next, we performed a GWAS of CUD cases against schizophrenia cases in the iPSYCH cohort (2,387 CUD cases and 1,789 individuals with schizophrenia (ICD-10 F20) without a CUD diagnosis). Smoking rates among schizophrenia cases is in the range of 60-90% (ref. 31 ), therefore comparable with the rates among CUD cases. By comparing the two groups with comparable smoking rates, we would expect the association signal to disappear if smoking is the driving factor. The index variant rs56372821 was associated with CUD (P = 1.68 × 10
, OR = 0.76). The observed strong Table 2 In the analyses, individuals with a psychiatric diagnosis in the iPSYCH cohort were excluded, one disorder at a time, and an analysis without the controls was also conducted: without ADHD, without ASD, without bipolar disorder, without iPSYCH controls, without MDD and without schizophrenia. The GWASs were carried out using logistic regression; P values are two-sided. The P value for the association with CUD, the number of cases, frequency of the minor allele in cases, number of controls, frequency of the minor allele in controls, OR and s.e.m. are shown. For illustration, the OR and corresponding s.e.m. are given.
Articles Nature NeuroscieNce association, with only a slight increase in OR from 0.73 in the original CUD GWAS to 0.76, suggests that the signal is primarily driven by CUD and not confounded by tobacco smoking. Finally, no strong confounding of tobacco smoking at the polygenic level in the CUD GWAS was observed. This was evaluated using the iPSYCH CUD GWAS as training to generate CUD PRS in deCODE. The score explained more of the variance and was associated with a higher effect size for CUD risk (R 2 = 0.24%; OR = 1.17) than for tobacco smoking (R 2 = 0.10%, OR = 1.07) (Supplementary Table 10 ).
In summary, all four approaches suggest that the results reflect an association with CUD without a strong confounding from smoking, both with respect to the identified CUD risk locus and at the polygenic level.
Genetic overlap with other phenotypes. To evaluate the genetic overlap between CUD and a range of other phenotypes at the polygenic level, we conducted analyses of PRS for 22 phenotypes related to cognition, personality, psychiatric disorders, reproduction and smoking behavior (see Methods; a list of references to the GWAS of the 22 phenotypes and results can be found in Supplementary Table 11 ). The PRS for 8 phenotypes (three measures of cognitive performance, age at first birth, lifetime smoking, ADHD, depressive symptoms and schizophrenia) demonstrated a strong association with CUD (4.33 × 10 −4 < P < 7.44 × 10 ), were strongly negatively associated with the risk of CUD, a finding reinforced by the significantly negative association of PRS for human intelligence with CUD (z-score = −3.51; P = 4.33 × 10 −4 ). Our results suggest an overlap in genetic risk factors with a decrease in the OR for CUD with an increased number of educational years/increased cognitive performance ( Supplementary Fig. 3a-c) . The observed decreased risk of CUD with increased age at first birth (z-score = −7.41; P = 1.26 × 10
) supports the relationship with educational attainment since the number of educational years is known to correlate genetically with later birth of the first child 32 . To avoid confounding of psychiatric disorders in the PRS analyses, we excluded individuals among CUD cases and controls with a diagnosis of the psychiatric disorder being analyzed. The PRS for ADHD (z-score = 5.10; P = 3.45 × 10 ) were all associated with an increased risk for CUD (Fig. 4) .
Discussion
This study reports a genome-wide significant risk locus for diagnosed CUD replicated in an independent cohort. The locus is located intergenically on chromosome 8 (index variant rs56372821) and has an effect size (OR of 0.73), in line with findings for other 19, 33 . PRS analysis supported a high consistency of the CUD phenotypes analyzed in the discovery and replication cohorts from iPSYCH and deCODE, respectively, and supported the notion that the GWAS results reflect an association with CUD and not comorbid psychiatric disorders in the iPSYCH cohort. This also holds for the risk locus, where careful dissection with regard to the distribution of effect sizes for the index variant (rs56372821) over comorbid subgroups revealed no confounding effect from psychiatric disorders. This included an analysis excluding individuals with schizophrenia, which still revealed significant genome-wide association of rs56372821 with CUD. This supports the proposed hypothesis that the significant genome-wide signal observed for the CUD risk locus in schizophrenia 19 could be driven by a subgroup of schizophrenia cases having CUD.
Analysis of the imputed genetically regulated gene expression suggested that CHRNA2 underexpression in the cerebellum (and probably other brain regions) is involved in CUD. The cerebellum may play a role in addiction with regard to reward and inhibitory control 34 , and reward-anticipating responses 35 . The cerebellum has a high density of cannabinoid receptor 1 (CB1), which mediates the effect of Δ-9-tetrahydrohydrocannabinol (THC), the psychoactive compound in cannabis. Cerebellum has also been found to be affected by cannabis use in neuroanatomical studies, for example 36 . CHRNA2 encodes the nAChR α2 subunit, and there is no reported functional link between cannabis use and the α2 subunitcontaining nAChRs. We hypothesize three potential ways of how CHRNA2 may be involved in CUD: (1) substances in cannabis might interact directly with the α2 subunit-containing nAChRs since studies have found that cannabidiol, a non-psychoactive component of cannabis, inhibits the α7-containing nAChRs 37 ; (2) cannabis could indirectly affect the α2 subunit-containing nAChRs. After binding of an agonist (for example, acetylcholine), the nAChR responds by opening an ion-conducting channel across the plasma membrane. This causes depolarization of the membrane and can result in presynaptic neurotransmitter release including dopamine 38 . Since THC, the psychoactive compound of cannabis, has been found to affect the release of acetylcholine in various brain regions 39 , it could be speculated that this, through the α2 subunit-containing nAChRs, could affect dopamine release, a known neurotransmitter involved in addiction; (3) there could be a strong biological link between expression of CHRNA2 and CNR1. This hypothesis is based on evaluation of gene expression correlations from genome-wide microarray gene expression profiles in the Allen Brain Atlas (http://www.brain-map.org/). Of all the genes evaluated (58,692 probes analyzed), CNR1 demonstrated the strongest negative correlation with CHRNA2 expression (r max = −0.498; Supplementary Fig. 4) . The signal was driven by opposite expression patterns in several brain tissues, for example, in the cerebellum where CNR1 had a relatively high expression in the cerebellar cortex and CHRNA2 had a relatively low expression; the opposite was observed for the cerebellar nuclei ( Supplementary Fig. 4 ). This suggests the existence of a currently uncharacterized biological interaction between the endocannabinoid system and the α2 subunit-containing nAChRs, where the identified risk locus associated with decreased CHRNA2 expression could be related to increased CNR1 expression.
The observed association of CHRNA2 underexpression with CUD, also implies that the α2 subunit can be a potential drug target in the treatment of CUD, by using an agonist selective for α2 subunit-containing nAChRs. The impact of some compounds with an agonistic effect on the α2 subunit-containing nAChRs, such as NS9283 (ref. 40 ), ABT-418 (ref. 41 ) and TC-1734 (ref.
42
), have already been studied primarily due to their potential impact on memory and cognitive processes 40, 42 . Since CHRNA2 and other nicotine receptor genes have been identified as risk loci for nicotine dependence and smoking behavior 27, 30 , the potential confounding from smoking was evaluated carefully. The results of all our analyses suggest that CUD is not strongly confounded by smoking. Furthermore, our results suggest that the identified CUD risk locus, which is also significantly associated with smoking genome-wide 30 , albeit with significantly lower effect size than observed for CUD, has a pleiotropic effect on both smoking and CUD in the general population, with the greatest impact on CUD risk. Additionally, a recent GWAS of lung cancer identified a genome-wide significant locus just upstream CHRNA2 (ref. 43 ). In linkage disequilibrium terms, this locus is distinct from the locus identified in the present study; however, the risk allele was also associated with decreased CHRNA2 expression in the cerebellum. In analyses of smoking behavior, the lung cancer risk allele was reported to be nominally associated with smoking and age of initiation 43 . This result is in line with our observation of the CUD risk variant; thus, decreased CHRNA2 expression is associated with younger age at first diagnosis of CUD.
Finally, we cannot exclude other relevant genes in the region, such as epoxide hydrolase 2 (EPHX2). This gene encodes soluble epoxide hydrolase involved in xenobiotic metabolism by degrading potentially toxic epoxides. While EPXH2 is not one of the main metabolizers of THC, some involvement is possible since soluble epoxide hydrolase may act on at least some endocannabinoid metabolites and metabolites of Δ-8-THC
44
. At the polygenic level, an increased load of variants associated with measures of decreased cognitive performance was associated with CUD. This suggests an underlying genetic component causing the decreased educational performance related to cannabis use in numerous epidemiological studies, for example, Horwood et al.
45
.
The direction of causation is unclear; it is unknown if the relationship is caused by cannabis use and subsequent disengagement from ) is given on the x axis and the P value from the logistic regression for the association of the PRS with CUD is shown on the y axis (based on the analyses of 2,387 individuals with CUD and 48,985 controls). The blue line indicates statistical significance (P = 0.0023, correcting for 22 tests). In the PRS analyses of psychiatric disorders, individuals having a diagnosis of the respective psychiatric disorder being analyzed (ADHD, schizophrenia, depressive symptoms and MDD) were excluded in the CUD target sample. SSGAC, Social Science Genetic Association Consortium. ). However, we cannot rule out whether the overlap involves variants with pleiotropic effects, or if the overlap in general is caused by heterogeneity among schizophrenia cases due to a subgroup comorbid with CUD, in line with the CUD risk locus identified in the present study.
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In summary, we identified a genome-wide significant CUD locus, which was replicated in an independent sample. An impact of the locus on earlier age of first diagnosis was further suggested. CHRNA2 was implicated in CUD through analyses of the imputed genetically regulated gene expression, showing decreased CHRNA2 expression in the cerebellum (and other brain regions) of individuals with CUD. This is an intriguing result; however, further studies are needed to evaluate whether CHRNA2 could be a potential therapeutic target for CUD treatment. The identified locus is in a region previously associated with schizophrenia 19 , smoking 30 and lung cancer 43 . Regarding the identified risk locus, our GWAS results did not seem to be confounded by either smoking or psychiatric disorders. Larger GWASs and functional studies are needed to further explain the biological mechanisms underlying the phenotypic associations observed for this region.
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Processing of samples, genotyping, quality control and imputing were done in 23 waves. In this study, individuals from the first four waves were excluded since only a few CUD cases were present in these waves (range, 0-15 cases). The waves represent approximate birth years; the four waves that were excluded represent, to a large extent, individuals who in 2013 (the time of extraction of register diagnoses) were children. The mean age of cases is 24.77 years (s.d. = 5.32) and mean age of controls is 22.67 years (s.d. = 3.86). The control group is younger and the age span wider than for the cases. The presence of younger individuals among the controls may have reduced the power since some controls eventually become cases; it also reduces the risk of discovering a false positive association.
The study was approved by the Danish Data Protection Agency and the Scientific Ethics Committee in Denmark.
Statistical analyses.
Genotyping, quality control and GWASs. DNA was extracted from dried blood spot samples and whole genome amplified in triplicates, as described previously 56, 57 . Genotyping was performed at the Broad Institute of Harvard and MIT using Illumina's BeadArrays (PsychChip; Illumina) according to the manufacturer's protocols. Genotypes were a result of merging call sets from three different calling algorithms (GenCall, Birdseed and zCall). GenCall 58 and Birdseed 59 were used to call genotypes with a MAF > 0.01 and zCall 60 was used to call genotypes with a MAF < 0.01. The merging was done after pre-quality control on individual call sets.
Stringent quality control was applied and only samples with an individual call rate (>0.98) and genotypes with high call rate (>0.98), no strong deviation from Hardy-Weinberg equilibrium (P > 1 × 10 −6 in controls or P > 1 × 10 −10 in cases) and low heterozygosity rates (F het < 0.2) were included. Genotypes were phased and imputed using phase 3 of the 1000 Genomes Project 61,62 imputation reference panel and SHAPEIT 63 and IMPUTE2 (ref.
64
). Relatedness and population stratification were evaluated using a set of high-quality markers (genotyped autosomal markers with a MAF > 0.05, Hardy-Weinberg equilibrium P > 1 × 10 −4 and SNP call rate > 0.98), which were pruned for linkage disequilibrium (r 2 < 0.075) resulting in a set of 37,425 pruned markers. (Markers located in the long-range linkage disequilibrium regions defined by Price et al. 65 were excluded.) Genetic relatedness was estimated using PLINK v.1.9 (refs. 66, 67 ) to identify first-and second-degree relatives (π > 0.2); one individual was excluded from each related pair (cases preferred over controls). Genetic outliers were identified for exclusion based on principal component analysis (PCA) using EIGENSOFT 7.2.1 (refs. 68, 69 ). A genetically homogenous sample was defined based on a subsample of individuals being Danes for three generations (identified based on register information about the birth country of the individuals, their parents and grandparents). The subsample of Danes was used to define the center based on the mean values of principal components 1 and 2. Subsequently, principal components 1 and 2 were used to define a genetically homogenous population by excluding individuals outside an ellipsoid with the axes greater than six s.d. from the mean. After outlier exclusion, PCA was redone and the principal components from this analysis were included in the association analysis.
The association analysis was done using logistic regression and imputed marker dosages. The following covariates were used: principal components 1-4 and principal components from the PCA associated with case-control status; the 19 data processing waves; and diagnosis of major psychiatric disorders studied by iPSYCH (Supplementary Table 1) . Results for 9,729,295 markers were generated; subsequently, markers with an imputation INFO score < 0.7 (n = 608,367), markers with a MAF < 0.01 (n = 10,220) and multiallelic markers (n = 143,083) were removed. In total, after filtering, 8,969,939 markers remained for further analysis. All analyses of the iPSYCH sample were performed at the secured national GenomeDK high-performance computing cluster in Denmark (https://genome. au.dk).
We evaluated the impact of age on the identified risk locus on chromosome 8. We corrected for age using age coded as a binary variable, with the mean age of cases (24.77 years (s.d. = 5.32)) as a guideline for the cutoff, grouping all individuals aged <25 into one group (1,164 cases and 29,818 controls) and individuals aged > 24 into another group (1,223 cases and 19,167 controls). Due to the low age span among cases, it did not make sense biologically to divide the cases into smaller age bins. Correcting for age did not have an impact on the strong association of the risk locus on chromosome 8 (rs5637282; P = 1.082 × 10
−11
).
Replication. The genome-wide significant locus on chromosome 8 was replicated in an independent European cohort consisting of 5,501 cases with diagnosed CUD and 301,041 population controls collected by deCODE genetics. The characteristics of the SAA treatment sample have been described previously 20 ; currently, diagnoses at Vogur Hospital are made using the DSM-V, but most of the diagnoses in this study are based on DSM-IV or DSM-IIIR. The genotypes were obtained based on SNP array data and whole genome sequencing using long-range phasing and two types of imputations 70 . For the replication study, markers were looked up in the results of a GWAS performed using logistic regression, which treated disease status as the response and genotype counts as the covariates. Other available individual characteristics that correlate with disease status were also included in the model as nuisance variables, using methods described previously 71 . The resulting P values were corrected for inflation using genomic controls (correction factor = 1.42). Nine genetic variants, all representing the same association signal on chromosome 8 with P < 1 × 10
, were looked up in the deCODE results. The variants in the locus were selected based on linkage disequilibrium (0.2 < r 2 < 0.7). We included additional markers besides the index SNP to be able to evaluate the consistency of direction of association in the replication cohort over a set of variants located in the associated risk locus. The data were meta-analyzed using summary statistics and an inverse variance-weighted fixed effects model, implemented with the software METAL (version 2011-03-25) 72 . All tested variants demonstrated consistent direction of association in the replication cohort.
CUD PRS analysis in deCODE.
A PRS was computed from the iPSYCH CUD GWAS summary data using the LDpred method 73 . Only markers with a single rs-name (reference SNP ID) from the GWAS were used. Associations between PRS and CUD (2,257 cases and 145,069 controls), schizophrenia (729 cases and 153,007 controls), bipolar disorder (1,751 cases and 151,923 controls) and smoking (46,941 individuals reporting being a regular smoker throughout their life and 20,602 controls who had never been regular smokers) was computed using linear regression. Covariates were sex, age and the first ten principal components. Association P values were corrected for inflation using linkage disequilibrium score regression.
Heritability. SNP heritability (h 2 SNP ) was estimated by linkage disequilibrium score regression 74 using summary statistics from the GWAS of CUD and precomputed linkage disequilibrium scores (available at https://github.com/bulik/ldsc). SNP heritability was calculated on the liability scale using a 1% prevalence of CUD in the population. The h 2 SNP estimated by linkage disequilibrium score regression was inaccurate since the ratio between the estimated h 2 SNP and the s.e.m. was <4 (h 2 SNP / s.e.m. = 2.86). Therefore, the h 2 SNP was also estimated using the GCTA 75 . A genomic relationship matrix between all pairwise combinations of individuals was estimated for each autosome separately and subsequently merged using the GCTA software. The strict best-guess genotypes (that is, 4,299,887 SNPs with an INFO score > 0.8, missing rate < 0.01 and MAF > 0.01) from imputation with phase 3 of the 1000 Genomes Project were used for genomic relationship matrix estimation. Univariate genome-based restricted maximum likelihood analyses in the GCTA was used to estimate h 2 SNP on the liability scale, using the combined genomic relationship matrix and the same covariates as in the GWAS.
Leave-one-phenotype-out GWAS. In the GWAS of CUD, using covariates, we corrected for five major psychiatric disorders analyzed in iPSYCH (Supplementary  Table 1 ). However, to further evaluate the potential impact on the association signal of the index variant from the psychiatric phenotypes, sensitivity analyses were performed where one phenotype at a time was excluded from the association analysis. The phenotypes evaluated were schizophrenia, bipolar disorder, MDD, ADHD, ASD and individuals not having any of the five diagnoses. GWASs were Cross-disorder GWAS to evaluate the general association of rs56372821 with psychiatric disorders. To investigate the possibility of the risk locus at chromosome 8 being a general risk locus for psychiatric disorders, we conducted a cross-disorder GWAS based on the same individuals included in the CUD GWAS. All individuals with a diagnosis of schizophrenia (ICD-10 F20), bipolar disorder (ICD-10 F30-F31), ADHD (ICD-10 F90.0), ASD (ICD-10 F84.0, F84.1,  F84 .5, F84.8 and F84.9) and MDD (ICD-10 F32-F33) were used as cases (35,006 individuals); 16,366 individuals without any of the listed psychiatric disorders were used as controls. The GWAS was conducted using wave as the covariate and principal components from the PCA (generated as described for the CUD GWAS).
We redid the cross-disorder GWAS excluding all individuals with a CUD diagnosis (removing 2,290 individuals from the case group and 97 individuals from the control group), reducing the sample size to 32,716 cases and 16,269 controls. The GWAS was conducted using the principal components from the PCA and wave as the covariate.
Permutation-based evaluation of the OR of rs56372821 for schizophrenia with and without CUD. We applied a permutation-based approach to evaluate how the inclusion and exclusion of individuals with CUD affected the association of our index variant rs56372821 with schizophrenia. The analyses were based on the iPSYCH sample consisting of 2,281 schizophrenia cases and 23,134 populationbased controls (genotyping, quality control and imputation were done using the same procedures as explained earlier). ORs were obtained with the glm() function in R, using dosage data from the imputed SNP rs56372821, including principle components 1-4, and principal components significantly associated with schizophrenia and/or CUD and genotyping wave as the covariate.
In the association analysis of schizophrenia, the OR 56372821 = 0.9 (0.81-0.99; 95% confidence interval). When all individuals with CUD were excluded, in cases and controls (1,727 cases and 23,033 controls) the OR rs56372821 = 0.97 (0.87-1.09; 95% confidence interval). To evaluate whether this change in OR was due to the removal of individuals with CUD (554 cases with CUD and 101 controls removed) or reduction in sample size, a null distribution of ORs was generated by randomly removing 554 individuals from the schizophrenia cases and 101 individuals from the controls (removing a total of 655 individuals). This permutation of sample exclusion was done 9,999 times to generate the null distribution of the OR for rs56372821. To obtain a two-sided P value, the observed log(OR rs56372821 ) = −0.03 was mirrored around the mean log(OR rs56372821 ) of the null distribution, as shown in Supplementary Fig. 1 . Removal of individuals with CUD (554 schizophrenia cases and 101 controls) changed the OR of rs56372821 significantly, compared to random removal of the same number of schizophrenia cases and controls (twosided P = 0.0027), producing a significant increase of OR rs56372821 compared to random removal (one-sided P = 0.0015).
mtCOJO conditioning for the effect of smoking. The analysis was performed using summary statistics from the CUD GWAS and the GWAS of smoking initiation 30 (excluding 23andMe data, 547,219 individuals and 11,733,344 variants). The conditional analysis was run using mtCOJO 46 (implemented in the GCTA (v. 1.91) 75 ) using standard procedures. Variants selected for conditioning were genome-wide significant in the smoking GWAS (P < 5 × 10 −8 ) and not in linkage disequilibrium (r 2 < 0.05), with a variant with a lower P value (61 variants). One variant was removed due to evidence of pleiotropy (heterogeneity in dependent instruments outlier threshold P = 0.01).
Simulation analysis to evaluate confounding by tobacco smoking. A simulation analysis was conducted to evaluate how likely it is to observe an OR of 0.728 if the association signal is driven primarily by smoking, assuming a true OR of smoking = 0.954 (ref. 30 ). We divided individuals into six strata by assigning them a unique phenotype using the following hierarchy: (1) schizophrenia; (2) bipolar disorder; (3) ASD; (4) ADHD; (5) MDD; and (6) controls. We assumed a dominant model, where homozygous and heterozygous carriers of the minor allele of rs56372821 were treated equally. (See Supplementary Table 9 for the distribution of individuals having the major allele or at least one minor allele among the strata.)
The null hypothesis was that rs56372821 only affects CUD via its effect on tobacco smoking, which has an OR of 0.954 (TOR) 30 . We assumed a prevalence of CUD among tobacco users of 0.045 (CT) 76 and a CUD prevalence among tobacco non-users of 0.01 (Ct) 5 , independently of the six groups. Given the prevalence of tobacco smoking (PRE) among one of the six groups, we could calculate the probability of tobacco smoking for minor (Tm) and major (TM) allele carriers among the groups, using the total probability formulae PRE = MAF Tm + (1 − MAF)TM and OR TOR = (Tm(1 − TM))/(TM(1 − Tm)). First, we simply simulated the tobacco use status of each individual using the probabilities Tm and TM; further, we simulated the CUD status using the probabilities CT and Ct and computed the simulated common Cochran-Mantel-Haenszel OR for CUD. We did not require the total number of simulated CUD cases per stratum to match the observed numbers because we wanted to keep this approach as simple as possible. We repeated the simulation 100,000 times and compared the results with the observed OR of 0.728 for CUD, obtaining an estimator of the P value for the null hypothesis with a variance <1/(4 × 100,000) = 0.0000025. This was repeated for various estimates of PRE among the six groups: a total of 2 12 combinations from the six sets of PRE schizophrenia ∈ (0.6, 0.7, 0.8, 0.9), PRE bipolar disorder ∈ (0.3, 0.4, 0.5, 0.6), PRE ASD ∈ (0.05, 0.1, 0.15, 0.2), PRE ADHD ∈ (0.1, 0.2, 0.3, 0.4), PRE MDD ∈ (0.2, 0.3, 0.4, 0.5) and PRE controls ∈ (0.1, 0.15, 0.2, 0.25). The largest P value encountered was 8.69 × 10 −3 , making the null hypothesis very unlikely. The simulation was repeated including information about the stratification of the six phenotypes (described earlier) over the genotyping waves. The genotyping wave was assumed to have no effect on the various probability parameters of the simulation; this time, simulations were repeated only 10,000 times. The largest P value encountered was 4.0 × 10
; the variance of this estimator was <1/(4 × 10,000) = 0.000025, thus rejecting the null hypothesis.
GWAS of CUD cases against schizophrenia cases. This GWAS was based on individuals in the iPSYCH cohort and compared 2,387 CUD cases (ICD-10 F12.1-F12.9) against 1,789 individuals diagnosed with schizophrenia (ICD-10 F20) without a CUD diagnosis. Quality control procedures with respect to individual and genotyping were the same as described for the CUD GWAS; association was calculated using logistic regression, corrected for genotyping wave and principal components from the PCA.
Association with age at first diagnosis. To test for the potential impact of the risk locus on age at first diagnosis, a case-only study was performed testing for the association of the index variant (rs56372821) and variants in linkage disequilibrium with this (r 2 > 0.7; 19 variants) with age at first diagnosis. The date of diagnosis was identified from register information in the Danish Psychiatric Central Research Register 52 . The analysis for association with age at first diagnosis (natural logarithm (age at first diagnosis)) was done using linear regression and the same covariates as used in the GWAS (principal components, wave and psychiatric disorders). A dominant model with regard to the risk allele was applied.
Analysis of the imputed genetically regulated gene expression. The genetically regulated gene expression was imputed in 11 brain tissues using PrediXcan v.6 data 77 (models downloaded from https://github.com/hakyimlab/PrediXcan). PrediXcan was used to impute the transcriptome for the cases and controls using SNP weights derived from models trained on reference transcriptome datasets including ten brain tissues from the GTEx 78 (https://www.gtexportal.org/home/) and transcriptome data from the dorsolateral prefrontal cortex generated by the CommonMind Consortium 79, 80 . The models were trained on 1,000 genome SNPs and contained only gene expression prediction models with a false discovery rate <5%. Gene expression levels in the iPSYCH data were imputed wave-wise; subsequently, the imputed data were merged. We tested for the association of 2,459-10,930 protein-coding genes (depending on the tissue; see Supplementary  Table 6 ) with CUD using logistic regression. The analysis was based on the same individuals who were included in the GWAS (thus, genetic outliers and related individuals were removed) and corrected using genotyping wave and psychiatric disorders as the covariates, as well as the same principal components from the PCA used in the GWAS. Since gene expression in different brain tissues is highly correlated, we corrected the P value for each gene by the total number genes tested in all tissues with a valid model available for the gene; regarding CHRNA2, we corrected for 13,166 genes tested in three tissues. Thus, P < 3.8 × 10 −6 (0.05/13,166) was considered statistically significant for this gene. This is in line with recent approaches used to correct for multiple testing in transcriptome-wide association studies using imputed gene expression 81 .
PRS analyses. PRS analyses were done using GWAS summary statistics from 22 GWASs (Supplementary Table 11 ). The summary files were downloaded from public databases and processed with the MUNGE script, which is part of the LDscore regression software 74 . All variants with INFO < 0.9, MAF < 0.01, missing values, out-of-bounds P values, ambiguous strand alleles and duplicated rs-IDs were removed using the MUNGE script. In addition, multiallelic variants and insertions and deletions were removed. The processed summary files were then LD-clumped using PLINK 1.9, with the following parameter settings: -clump-p1 1-clump-p2 1-clump-r2 0.1-clump-kb 500. The clumped file was used as the training dataset. Genetic risk scores were estimated at different P thresholds for SNP inclusion: 5 × 10 ; 0.01; 0.05; 0.1; 0.2; 0.5; and 1.0 for all individuals in the target sample (CUD cases and controls) from the genotype dosages using PLINK's '-score' method, with default arguments. However, the PRS scores for ADHD were generated using the approach described by Demontis et al. 33 . For each P value threshold, the variance in the phenotype explained by the PRS was estimated using Nagelkerke's R (R package BaylorEdPsych version 0.5); the association of PRS with CUD was estimated using logistic regression, including the same covariates used in the GWAS analysis (principal components from the PCA and the psychiatric disorders listed in Supplementary Table 1 ). In the PRS analyses of psychiatric disorders (ADHD, schizophrenia and depression-related phenotypes), individuals with a diagnosis of the disorder being analyzed were 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data collection
Genotyping was performed at the Broad Institute of Harvard and MIT (Cambridge, MA, USA) using Illumina's Beadarrays (PsychChip; Illumina, CA, San Diego, USA) according to the manufacturer's protocols. Genotypes were a result of merging callsets from the calling algorithms GenCall and Birdseed
Data analysis
Quality control and association analyses were done using the Ricopili pipeline: https://github.com/Nealelab/ricopili, which include the follwoing software: Plink 1.9, Eigensoft 6.1.3, METAL 2011-03-25. Association analysis of the genetic regulated gene-expression was done using PrediXcan (https://github.com/hakyimlab/PrediXcan; version 6 data) SNP heritability was estimated using LD score regression v.1.0.0 (https://github.com/bulik/ldsc) and LD hub (http:// ldsc.broadinstitute.org/) and GCTA v1.26.0 Meta analysis with the replication sample done using METAL 2011-03-25 Polygenetic risk score analysis were done using Plink 1.9 and the R package 'BaylorEdPsych' mtCOJO analysis was done using GCTA implemented in version gcta_1.91.7
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Sample size
No sample size calculation was made. Previous studies of polygenic psychiatric disorders (e.g. schizophrenia) have demonstrated that high numbers of cases and controls are needed in order to detect genome-wide significant loci. In order to maximise power, we based our analyses on the maximal possible sample size from the iPSYCH sample (2,387 cases and 48,985 controls), which should yield enough power to detect a few loci/common variants with low effect sizes.
Data exclusions Following standard procedures for GWAS related individuals and genetic outliers were excluded in order to avoid the risk of spurious findings and associations arising due to population stratification. Related individuals were removed based on based on identity by state analysis and genetic outliers were identified based on principal component analysis.
Replication
The genome-wide significant locus identified in the discovery GWAS was replicated with success in an independent cohort consisting of 5,501 cases and 301,041 controls from Iceland.
Randomization Allocation into groups was not random. Individuals were allocated into the case group based on having a diagnosis of cannabis use disorder (ICD10 diagnosis code: F12.1-F12-9). The controls should not have a diagnosis of cannabis use disorder.
Blinding
In iPSYCH, diagnoses are drawn from registries. These are administrative data bases populated by data from the clinicians long before the current study. The blood samples are pulled from a biobank. Hence, the study participants and diagnosing clinicians are blinded with respect to this study. Genotyping is done on a massive scale on 85.000 individuals on 500.000 variables (which by imputation is expanded to ~10 million variables), and the data is generated without a specif goal or effect in mind except for an overall goal of investigating the genetic and environmental effects on psychiatric disorders. So although it is in principle possible for analysts in the lab to look up crude diagnostic data for a sample, it will not change the genotyping. For the replication we include data from deCODE Genetics. Their design was different, but analyses analogous.
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